Samjin Pharmaceuticals Co., Ltd. (005500.KS)
KRW 18280.0
(-0.33%)
KRW 18280.0
(-0.33%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 116.23 Billion KRW | 36.47% |
| 2022 | 85.17 Billion KRW | 82.91% |
| 2021 | 46.56 Billion KRW | 537.88% |
| 2020 | -10.63 Billion KRW | 65.03% |
| 2019 | -30.4 Billion KRW | 0.95% |
| 2018 | -30.69 Billion KRW | -71.37% |
| 2017 | -17.91 Billion KRW | -515.63% |
| 2016 | -2.91 Billion KRW | -110.35% |
| 2015 | 28.11 Billion KRW | -7.24% |
| 2014 | 30.3 Billion KRW | -32.53% |
| 2013 | 44.92 Billion KRW | 10.89% |
| 2012 | 40.5 Billion KRW | -3.78% |
| 2011 | 42.1 Billion KRW | 5.76% |
| 2010 | 39.8 Billion KRW | -22.69% |
| 2009 | 51.49 Billion KRW | 23.8% |
| 2008 | 41.59 Billion KRW | 20.56% |
| 2007 | 34.49 Billion KRW | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 105.41 Billion KRW | -9.31% |
| 2024 Q2 | 104.88 Billion KRW | -0.5% |
| 2023 Q4 | 116.23 Billion KRW | 5.81% |
| 2023 Q1 | 92.13 Billion KRW | 8.18% |
| 2023 Q2 | 109.5 Billion KRW | 18.85% |
| 2023 FY | 116.23 Billion KRW | 36.47% |
| 2023 Q3 | 109.85 Billion KRW | 0.32% |
| 2022 Q4 | 85.17 Billion KRW | 6.31% |
| 2022 Q2 | 69.51 Billion KRW | 25.26% |
| 2022 Q1 | 55.49 Billion KRW | 19.19% |
| 2022 FY | 85.17 Billion KRW | 82.91% |
| 2022 Q3 | 80.11 Billion KRW | 15.24% |
| 2021 Q3 | 21.02 Billion KRW | 54.54% |
| 2021 Q2 | 13.6 Billion KRW | 315.92% |
| 2021 FY | 46.56 Billion KRW | 537.88% |
| 2021 Q1 | -6.29 Billion KRW | 40.76% |
| 2021 Q4 | 46.56 Billion KRW | 121.52% |
| 2020 FY | -10.63 Billion KRW | 65.03% |
| 2020 Q3 | -23.62 Billion KRW | 23.42% |
| 2020 Q4 | -10.63 Billion KRW | 54.99% |
| 2020 Q1 | -38.95 Billion KRW | -28.12% |
| 2020 Q2 | -30.85 Billion KRW | 20.8% |
| 2019 Q4 | -30.4 Billion KRW | -53.11% |
| 2019 Q3 | -19.85 Billion KRW | -13.79% |
| 2019 FY | -30.4 Billion KRW | 0.95% |
| 2019 Q1 | -20.56 Billion KRW | 33.01% |
| 2019 Q2 | -17.45 Billion KRW | 15.14% |
| 2018 Q1 | -33.13 Billion KRW | -84.96% |
| 2018 Q3 | -40.59 Billion KRW | -33.32% |
| 2018 Q2 | -30.44 Billion KRW | 8.11% |
| 2018 Q4 | -30.69 Billion KRW | 24.37% |
| 2018 FY | -30.69 Billion KRW | -71.37% |
| 2017 Q3 | -9.3 Billion KRW | -461.37% |
| 2017 Q2 | -1.65 Billion KRW | 83.16% |
| 2017 Q1 | -9.84 Billion KRW | -238.21% |
| 2017 FY | -17.91 Billion KRW | -515.63% |
| 2017 Q4 | -17.91 Billion KRW | -92.53% |
| 2016 Q1 | 16.05 Billion KRW | -42.9% |
| 2016 Q3 | 3.61 Billion KRW | -76.02% |
| 2016 Q2 | 15.08 Billion KRW | -6.04% |
| 2016 Q4 | -2.91 Billion KRW | -180.47% |
| 2016 FY | -2.91 Billion KRW | -110.35% |
| 2015 FY | 28.11 Billion KRW | -7.24% |
| 2015 Q4 | 28.11 Billion KRW | -5.47% |
| 2015 Q3 | 29.74 Billion KRW | -7.82% |
| 2015 Q2 | 32.26 Billion KRW | 12.38% |
| 2015 Q1 | 28.71 Billion KRW | -5.26% |
| 2014 Q2 | 33.73 Billion KRW | -3.67% |
| 2014 Q3 | 32.33 Billion KRW | -4.15% |
| 2014 FY | 30.3 Billion KRW | -32.53% |
| 2014 Q4 | 30.3 Billion KRW | -6.28% |
| 2014 Q1 | 35.02 Billion KRW | -22.04% |
| 2013 Q3 | 49.94 Billion KRW | -0.5% |
| 2013 Q4 | 44.92 Billion KRW | -10.06% |
| 2013 FY | 44.92 Billion KRW | 10.89% |
| 2013 Q1 | 38.69 Billion KRW | -4.48% |
| 2013 Q2 | 50.19 Billion KRW | 29.72% |
| 2012 Q2 | 24.76 Billion KRW | -25.94% |
| 2012 Q1 | 33.43 Billion KRW | -20.58% |
| 2012 FY | 40.5 Billion KRW | -3.78% |
| 2012 Q4 | 40.5 Billion KRW | 73.29% |
| 2012 Q3 | 23.37 Billion KRW | -5.59% |
| 2011 Q3 | 57.35 Billion KRW | 8.63% |
| 2011 Q4 | 42.1 Billion KRW | -26.59% |
| 2011 FY | 42.1 Billion KRW | 5.76% |
| 2011 Q1 | 54.13 Billion KRW | 35.98% |
| 2011 Q2 | 52.79 Billion KRW | -2.46% |
| 2010 Q4 | 39.8 Billion KRW | -6.93% |
| 2010 Q3 | 42.77 Billion KRW | -9.61% |
| 2010 FY | 39.8 Billion KRW | -22.69% |
| 2010 Q1 | 53.49 Billion KRW | 3.89% |
| 2010 Q2 | 47.31 Billion KRW | -11.55% |
| 2009 Q2 | 46.12 Billion KRW | 4.47% |
| 2009 FY | 51.49 Billion KRW | 23.8% |
| 2009 Q4 | 51.49 Billion KRW | 0.73% |
| 2009 Q3 | 51.11 Billion KRW | 10.82% |
| 2009 Q1 | 44.15 Billion KRW | 6.15% |
| 2008 Q4 | 41.59 Billion KRW | -9.37% |
| 2008 Q2 | 40.32 Billion KRW | 9.19% |
| 2008 Q1 | 36.92 Billion KRW | 7.04% |
| 2008 Q3 | 45.89 Billion KRW | 13.83% |
| 2008 FY | 41.59 Billion KRW | 20.56% |
| 2007 Q1 | 28.32 Billion KRW | 0.0% |
| 2007 FY | 34.49 Billion KRW | 0.0% |
| 2007 Q4 | 34.49 Billion KRW | 0.77% |
| 2007 Q3 | 34.23 Billion KRW | 8.1% |
| 2007 Q2 | 31.67 Billion KRW | 11.82% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1220.533% |
| Dong-A Socio Holdings Co., Ltd. | 572.02 Billion KRW | 79.68% |
| Ildong Holdings Co., Ltd. | 310.87 Billion KRW | 62.61% |
| HANDOK Inc. | 283.45 Billion KRW | 58.993% |
| Kukje Pharma Co., Ltd. | 20.07 Billion KRW | -479.093% |
| Yuhan Corporation | -69.18 Billion KRW | 268.005% |
| Dong-A ST Co., Ltd. | 193.95 Billion KRW | 40.069% |
| SAMSUNG PHARM. Co., LTD. | -3.68 Billion KRW | 3253.621% |
| Hanmi Pharm. Co., Ltd. | 517.88 Billion KRW | 77.556% |
| Hanall Biopharma Co.,Ltd | -32.43 Billion KRW | 458.402% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -53.6% |
| Dong Sung Bio Pharm.Co.,Ltd. | 36.83 Billion KRW | -215.54% |
| MYUNGMOON Pharm co.,Ltd | 82.52 Billion KRW | -40.858% |
| Hana Pharm Co., Ltd. | 25.1 Billion KRW | -362.939% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1220.533% |
| Ilsung Pharmaceuticals Co., Ltd. | -159.84 Billion KRW | 172.717% |
| REYON Pharmaceutical Co., Ltd. | 200.94 Billion KRW | 42.155% |
| Aprogen pharmaceuticals,Inc. | 170.94 Billion KRW | 32.003% |
| JW Holdings Corporation | 480.68 Billion KRW | 75.819% |
| Ildong Pharmaceutical Co., Ltd. | 164.58 Billion KRW | 29.375% |
| Chong Kun Dang Pharmaceutical Corp. | 117.53 Million KRW | -98798.319% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 24.703% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -4843.465% |
| Hyundai Pharmaceutical Co., Ltd. | 23 Billion KRW | -405.345% |
| Samil Pharmaceutical Co.,Ltd | 174.97 Billion KRW | 33.569% |
| Jeil Pharmaceutical Co.,Ltd | 51.97 Billion KRW | -123.641% |
| Yuyu Pharma, Inc. | 8.8 Billion KRW | -1220.533% |
| Kwang Dong Pharmaceutical Co., Ltd. | 158.29 Billion KRW | 26.57% |
| Daewoong pharmaceutical Co.,Ltd | 358.17 Billion KRW | 67.548% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 24.703% |
| Yuhan Corporation | -69.18 Billion KRW | 268.005% |
| Jeil Pharma Holdings Inc | 135.99 Billion KRW | 14.527% |
| Yungjin Pharm. Co., Ltd. | 59.67 Billion KRW | -94.785% |
| Suheung Co., Ltd. | 429.14 Billion KRW | 72.915% |
| JW Pharmaceutical Corporation | 154.37 Billion KRW | 24.703% |
| Korea United Pharm Inc. | 16.42 Billion KRW | -607.677% |
| CKD Bio Corp. | 143.29 Billion KRW | 18.884% |
| Daewon Pharmaceutical Co., Ltd. | 116.06 Billion KRW | -0.146% |
| Dongwha Pharm.Co.,Ltd | -24.06 Billion KRW | 583.077% |
| Whan In Pharm Co.,Ltd. | -44.73 Billion KRW | 359.839% |
| Shin Poong Pharm.Co.,Ltd. | 2.35 Billion KRW | -4843.465% |
| Chong Kun Dang Holdings Corp. | 422.84 Billion KRW | 72.511% |
| Boryung Corporation | 187.72 Billion KRW | 38.082% |
| Bukwang Pharmaceutical Co., Ltd. | -71.84 Billion KRW | 261.799% |
| Ilyang Pharmaceutical Co.,Ltd | 75.67 Billion KRW | -53.6% |
| JW Lifescience Corporation | 26.09 Billion KRW | -345.51% |